Publications by authors named "Emanuele E Pivetta"
Ceftobiprole is a fifth-generation cephalosporin approved by European and American regulatory agencies for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP). Ceftobiprole administration is useful in severe CAP as well as HAP where the potential is to save other β-lactams including carbapenems or linezolid/vancomycin in clinical practice. The aim of this study was to report the real-world evidence of ceftobiprole in patients with CAP and HAP in a single center.
View Article and Find Full Text PDFBackground: For COVID-19 patients evaluated in the Emergency Department (ED), decision on hospital admission vs. home discharge is challenging. The 4C mortality score (4CMS) is a prognostication tool integrating key demographic/clinical/biochemical data validated for COVID-19 inpatients.
View Article and Find Full Text PDFArticle Synopsis
- The first wave of COVID-19 caused a significant drop in emergency department (ED) visits and hospital admissions for non-COVID-19 ailments, with visits decreasing by 66.4% during the peak.
- The study, conducted in an Italian city, highlighted a consistent reduction in ED visits post-wave, with decreases of around 25% sustained over months, especially among pediatric patients.
- While critical triage codes remained stable, non-COVID-19 hospital admissions fluctuated but showed a general trend of reduction throughout the study period.
Background: During orthotopic liver transplantation (OLT), liver graft ischemia-reperfusion injury (IRI) triggers a cytokine-mediated systemic inflammatory response, which impairs graft function and disrupts distal organ homeostasis. The objective of this prospective, observational trial was to assess the effects of IRI on lung and chest wall mechanics in the intraoperative period of patients undergoing OLT.
Methods: In 26 patients undergoing OLT, we measured elastance of the respiratory system (ERS), partitioned into lung (EL) and chest wall (ECW), hemodynamics, and fluid and blood product intake before laparotomy (T1), after portal/caval surgical clamp (T2), and immediately (T3) and, at 90 and 180 minutes post-reperfusion (T4 and T5, respectively).